Fluconazole prophylaxis in HIV disease, revisited: Editorial commentary

Clinical Infectious Diseases

Volumn 41, Issue 10, 2005, Pages 1481-1482

  Bozzette, Samuel A ^a,b  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE; PROTEINASE INHIBITOR;

CANDIDIASIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NOTE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HIV INFECTIONS; HUMANS;

EID: 27644516390     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497380     Document Type: Note

References (3)

1. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473-80 (in this issue).
2. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:700-5.
3. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-8.